ADCT - Karyopharm's XPOVIO Progress And Other News: The Good Bad And Ugly Of Biopharma
Karyopharm Collaborates with National Cancer Institute for XPOVIO Research
Karyopharm Therapeutics Inc. (KPTI) announced that it has inked a new collaboration with National Cancer Institute. The partnership will mainly focus on developing XPOVIO, an oral Selective Inhibitor of Nuclear Export (SINE) compound. Both the parties will work together on studies to assess the efficacy and safety of XPOVIO in various oncology indications.
Karyopharm will be dealing with National Cancer Institute’s Cancer Therapy Evaluation Program, as stated in Cooperative Research and Development Agreement (CRADA). Sharon Shacham of Karyopharm said, “The studies conducted under this